tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Pyxis Oncology initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Pyxis Oncology (PYXS) with a Buy rating and $5 price target The firm believes the market may incorrectly written off micvotabart pelidotin, a first-in-concept non-internalizing antibody-drug conjugate against the novel target extra-domain B splice variant of fibronectin in the tumor stroma. The analyst thinks Pyxis may have a viable development path for micvotabart.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1